Home LiteratureArticle Details
PMID: 11959586 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome.

Antimicrobial agents and chemotherapy ·Vol. 46 ·No. 5 ·2002-05-00 ·Pages 1481-91

Kim YK, Pai H, Lee HJ, Park SE, Choi EH, Kim J, Kim JH, Kim EC

Abstract

To determine the epidemiologic features and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolates, cases of bacteremia caused by these organisms in children were analyzed retrospectively. Among the 157 blood isolates recovered from 1993 to 1998 at the Seoul National University Children's Hospital, the prevalence of ESBL production was 17.9% among the E. coli isolates and 52.9% among the K. pneumoniae isolates. The commonest ESBLs were SHV-2a and TEM-52. A novel ESBL, TEM-88, was identified. Pulsed-field gel electrophoresis analysis of the ESBL-producing organisms showed extensive diversity in clonality. The medical records of 142 episodes were reviewed. The risk factors for bloodstream infection with ESBL-producing organisms were prior hospitalization, prior use of oxyimino-cephalosporins, and admission to an intensive care unit within the previous month. There was no difference in clinical severity between patients infected with ESBL-producing strains (the ESBL group) and those infected with ESBL-nonproducing strains (the non-ESBL group) at the time of presentation. However, the overall fatality rate for the ESBL group was significantly higher than that for the non-ESBL group: 12 of 45 (26.7%) versus 5 of 87 (5.7%) (P = 0.001). In a subset analysis of patients treated with extended-spectrum cephalosporins with or without an aminoglycoside, favorable response rates were significantly higher in the non-ESBL group at the 3rd day (6 of 17 versus 33 of 51; P = 0.035), the 5th day (6 of 17 versus 36 of 50; P < 0.05), and the end of therapy (9 of 17 versus 47 of 50; P < 0.001). In conclusion, the ESBL production of the infecting organisms has a significant impact on the clinical course and survival of pediatric patients with bacteremia caused by E. coli and K. pneumoniae.

MeSH Terms
Adolescent Anti-Bacterial Agents/therapeutic use Bacteremia/drug therapy,epidemiology,microbiology,physiopathology Child Child, Preschool Drug Resistance, Bacterial/genetics Electrophoresis, Gel, Pulsed-Field Escherichia coli/enzymology Escherichia coli Infections/drug therapy,epidemiology,microbiology,physiopathology Female Humans Infant Infant, Newborn Klebsiella Infections/drug therapy,epidemiology,microbiology,physiopathology Klebsiella pneumoniae/enzymology Male Prevalence Retrospective Studies Risk Factors Treatment Outcome beta-Lactamases/genetics,metabolism
Chemicals
Anti-Bacterial Agents beta-Lactamases
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Kim Yun-Kyung
Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.
Pai Hyunjoo
Lee Hoan-Jong
Park Su-Eun
Choi Eun-Hwa
Kim Jungmin
Kim Je-Hak
Kim Eui-Chong
References (32)
32 references, click to expand
  1. Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric oncology ward: clinical features and identification of different plasmids carrying both SHV-5 and TEM-1 genes.
    J Clin Microbiol. 1999 Dec;37(12):4020-7 PMID: 10565924
  2. Survey of extended-spectrum beta-lactamases in clinical isolates of Escherichia coli and Klebsiella pneumoniae: prevalence of TEM-52 in Korea.
    J Clin Microbiol. 1999 Jun;37(6):1758-63 PMID: 10325320
  3. Rapid discriminatory detection of genes coding for SHV beta-lactamases by ligase chain reaction.
    Antimicrob Agents Chemother. 2000 Jul;44(7):1860-4 PMID: 10858344
  4. Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates.
    Antimicrob Agents Chemother. 2001 Feb;45(2):480-4 PMID: 11158744
  5. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.
    J Clin Microbiol. 2001 Jun;39(6):2206-12 PMID: 11376058
  6. Identification of CTX-M-14 extended-spectrum beta-lactamase in clinical isolates of Shigella sonnei, Escherichia coli, and Klebsiella pneumoniae in Korea.
    J Clin Microbiol. 2001 Oct;39(10):3747-9 PMID: 11574608
  7. Evolution of TEM-related extended-spectrum beta-lactamases in Korea.
    Antimicrob Agents Chemother. 2001 Dec;45(12):3651-3 PMID: 11709362
  8. The use of analytical isoelectric focusing for detection and identification of beta-lactamases.
    J Gen Microbiol. 1975 May;88(1):169-78 PMID: 807678
  9. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens.
    Infection. 1983 Nov-Dec;11(6):315-7 PMID: 6321357
  10. Novel R-factor borne beta-lactamase of Escherichia coli confering resistance to cephalosporins.
    Infection. 1987 Jul-Aug;15(4):257-9 PMID: 3312022
  11. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns.
    Rev Infect Dis. 1988 Jul-Aug;10(4):867-78 PMID: 3263690
  12. A standard numbering scheme for the class A beta-lactamases.
    Biochem J. 1991 May 15;276 ( Pt 1):269-70 PMID: 2039479
  13. More extended-spectrum beta-lactamases.
    Antimicrob Agents Chemother. 1991 Sep;35(9):1697-704 PMID: 1952834
  14. beta-Lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime.
    J Infect Dis. 1992 Jun;165(6):1033-41 PMID: 1583320
  15. Molecular epidemiology of plasmid spread among extended broad-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates in a pediatric hospital.
    J Clin Microbiol. 1993 Feb;31(2):179-84 PMID: 8432800
  16. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins.
    Ann Intern Med. 1993 Sep 1;119(5):353-8 PMID: 8135915
  17. Extended-spectrum beta-lactamases in Escherichia coli and Klebsiella spp. in European septicaemia isolates.
    J Antimicrob Chemother. 1993 Oct;32(4):559-70 PMID: 8288497
  18. Genetics of extended-spectrum beta-lactamases.
    Eur J Clin Microbiol Infect Dis. 1994;13 Suppl 1:S2-11 PMID: 7821301
  19. Enterococcus faecium and Enterococcus faecalis bacteremia: acquisition and outcome.
    Clin Infect Dis. 1995 Feb;20(2):296-301 PMID: 7742433
  20. Cloning and sequence of the gene encoding a cefotaxime-hydrolyzing class A beta-lactamase isolated from Escherichia coli.
    Antimicrob Agents Chemother. 1995 Oct;39(10):2269-75 PMID: 8619581
  21. Molecular genetics of resistance to both ceftazidime and beta-lactam-beta-lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to beta-lactam therapy.
    J Infect Dis. 1996 Jan;173(1):151-8 PMID: 8537652
  22. Detection of extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli.
    J Clin Microbiol. 1996 Apr;34(4):908-11 PMID: 8815106
  23. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation.
    J Infect Dis. 1996 Sep;174(3):529-36 PMID: 8769610
  24. Sequences of beta-lactamase genes encoding CTX-M-1 (MEN-1) and CTX-M-2 and relationship of their amino acid sequences with those of other beta-lactamases.
    Antimicrob Agents Chemother. 1996 Feb;40(2):509-13 PMID: 8834913
  25. Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics.
    Clin Infect Dis. 1997 Jan;24 Suppl 1:S19-45 PMID: 8994778
  26. Nomenclature of TEM beta-lactamases.
    J Antimicrob Chemother. 1997 Jan;39(1):1-3 PMID: 9044020
  27. OXA-15, an extended-spectrum variant of OXA-2 beta-lactamase, isolated from a Pseudomonas aeruginosa strain.
    Antimicrob Agents Chemother. 1997 Apr;41(4):785-90 PMID: 9087490
  28. Rapid pulsed-field gel electrophoresis protocol for typing of Escherichia coli O157:H7 and other gram-negative organisms in 1 day.
    J Clin Microbiol. 1997 Nov;35(11):2977-80 PMID: 9350772
  29. Survey of Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: prevalence of SHV-12 and SHV-2a in Korea.
    J Clin Microbiol. 1998 May;36(5):1446-9 PMID: 9574728
  30. Trends in beta-lactam resistance among Enterobacteriaceae.
    Clin Infect Dis. 1998 Aug;27 Suppl 1:S100-6 PMID: 9710678
  31. The characteristics of extended-spectrum beta-lactamases in Korean isolates of Enterobacteriaceae.
    Yonsei Med J. 1998 Dec;39(6):514-9 PMID: 10097677
  32. Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia.
    Int J Infect Dis. 2000;4(1):21-5 PMID: 10689210
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
Published
2002-05-00
Pages
1481-91
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC127143
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com